Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04447534
Recruitment Status : Completed
First Posted : June 25, 2020
Last Update Posted : April 1, 2022
Sponsor:
Information provided by (Responsible Party):
Sherief Abd-Elsalam, Tanta University

Brief Summary:
we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.

Condition or disease Intervention/treatment Phase
COVID Drug: Chloroquine or hydroxychloroquine Drug: zinc Phase 3

Detailed Description:
we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19. As, zinc may be of value in these cases and may be of value in enhancing chloroquine effect.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 191 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?
Actual Study Start Date : June 23, 2020
Actual Primary Completion Date : July 15, 2020
Actual Study Completion Date : August 15, 2020


Arm Intervention/treatment
Experimental: Chloroquine or hydroxychloroquine
Chloroquine or hydroxychloroquine alone
Drug: Chloroquine or hydroxychloroquine
Chloroquine or hydroxychloroquine
Other Name: alexoquine, chloroquine, hydroquine

Experimental: Chloroquine or hydroxychloroquine with zinc
Chloroquine or hydroxychloroquine with zinc
Drug: Chloroquine or hydroxychloroquine
Chloroquine or hydroxychloroquine
Other Name: alexoquine, chloroquine, hydroquine

Drug: zinc
Zinc tablets




Primary Outcome Measures :
  1. Number of patients with improvement or mortality [ Time Frame: 2 weeks ]
    The number of patients with improvement or mortality.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with positive COVID-19.

Exclusion Criteria:

  • Contraindications or hypersensitivity to chloroquine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04447534


Locations
Layout table for location information
Egypt
Tanta university hospital, Assuit University, Ainshams University
Tanta, Egypt
Sponsors and Collaborators
Tanta University
Investigators
Layout table for investigator information
Principal Investigator: sherief Abd-Elsalam, Ass. Prof. ass. Prof. Tropical Medicine
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University
ClinicalTrials.gov Identifier: NCT04447534    
Other Study ID Numbers: tanta zinc chloroquine
First Posted: June 25, 2020    Key Record Dates
Last Update Posted: April 1, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydroxychloroquine
Chloroquine
Chloroquine diphosphate
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents
Amebicides
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Filaricides
Antinematodal Agents
Anthelmintics